I would like to say thank you, thank you and thank you for your kind donations towards the Barts-MS coronavirus antibody study. With gift aid, we have now passed the £10,000 milestone and will be able to start the first phase of the study. This is great news. To raise the additional money I won’t be running a double-marathon, but we have taken up your suggestion of hosting a series of...
As you know ProfK is a CLAD lad and we are gearing up to start ChariotMS with us going to use oral cladribine. Today I give you a link (See below) to a review on cladribine and as a COI The content has nothing to do with me. If you are considering the trial, make a cup of tea and you can read it for the next few minutes. Hope it doesn’t act as a sleeping tablet, as it is quite long. But it...
Barts-MS rose-tinted-odometer: ★★★★★ What should be our therapeutic target in MS? Reducing relapses and MRI activity, NEDA (no evident disease activity) or saving the end-organ (brain volume loss)? I have been pushing the for the latter, i.e. the most important treatment target must be protecting the end-organ and saving or protecting as many neurons, axons and synapses as possible in...
A cross-over trial of 3 different fatigue drugs showed no difference from the fake treatment. Maybe ProfG wil comment on this, but it shows why trials are done Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, Krysko K, Rutatangwa A, Auvray C, Aljarallah S, Jin C, Mowry E, McCulloch C, Waubant E. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue...
Hello, my name is Farhana and I am a third year Biomedical Sciences student at Queen Mary University of London. I was born and brought up in Rome and moved to the UK when I was 12 where I completed my GCSE and A-Levels. After completing my degree, I am hoping to study medicine and become a doctor specialising in neuroscience or paediatrics. I am hoping work around the world as my ambition to...
Barts-MS rose-tinted-odometer: ★★★★★ My accident, which has forced me to rest, has also given me time to reflect and think. I now realise that we are potentially at a crossroads that could allow us to reconfigure healthcare. The reasons for doing this are obvious. The current antiquated Victorian model of healthcare, which is fixed in time (synchronous) and place (geography), is too inflexible;...
This is one for the hard-core scientisty types, but you ask about how to get rid of EBV. Here is a type of vaccination. You engineer T cells tonget rid of EBV. This is a mouse study but the CAR-T technology can and has been used in humans CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease.Slabik C, Kalbarczyk M...
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.Iaffaldano P, Lucisano G, Patti F, Brescia Morra V, De Luca G, Lugaresi A, Zaffaroni M, Inglese M, Salemi G, Cocco E, Conte A, Ferraro D, Galgani S, Bergamaschi R, Pozzilli C, Salvetti M, Lus G, Rovaris M, Maniscalco GT, Logullo FO, Paolicelli D, Achille M, Marrazzo G, Lovato V, Comi...
Barts-MS rose-tinted-odometer: ★★★★★ About 5 or 6 years ago, when we decided to replace the term DAF (disease-activity free) with NEDA (no evident disease activity) as a treatment target MS we created space to allow us to ‘move the goalposts’, i.e. to let our treatment targets in MS evolve as new insights and new technologies emerged. This is particularly pertinent as the field now realises that...
In response to a comment Dr Saul Reyes has provided some slides
Barts-MS rose-tinted-odometer: ★★★★★ I love science; it is such a thrill. I think science historians will look back at 2020 and the impact COVID-19 has had on science and scientific publishing and will define a new scientific era as being AC19 (after COVID-19) and the other era as BC19 (before COVID-19). The reason why I say this is because some of the changes that COVID-19 has induced in the...